211245-14-6 Usage
Structural Features
Ethyl group: Attached at position 8
Pyrido-pyrimidin-7-one ring: Core structure
4-(4-methylpiperazin-1-yl)phenylamino group: Attached to position 2
Potential Pharmacological Properties
Anti-inflammatory
Antimicrobial
Anticancer
Medicinal Chemistry Applications
Drug development
Targeted therapy
Structure-activity relationship studies
Research and Analysis Needs
Pharmacokinetics
Toxicology
Clinical trials for efficacy and safety validation
Check Digit Verification of cas no
The CAS Registry Mumber 211245-14-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,1,2,4 and 5 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 211245-14:
(8*2)+(7*1)+(6*1)+(5*2)+(4*4)+(3*5)+(2*1)+(1*4)=76
76 % 10 = 6
So 211245-14-6 is a valid CAS Registry Number.
211245-14-6Relevant articles and documents
Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
-
, (2008/06/13)
This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
Barvian,Boschelli,Cossrow,Dobrusin,Fattaey,Fritsch,Fry,Harvey,Keller,Garrett,La,Leopold,McNamara,Quin,Trumpp-Kallmeyer,Toogood,Wu,Zhang
, p. 4606 - 4616 (2007/10/03)
The identification of 8-ethyl-2-phenylamino-8H-pyrido [2,3-d]pyrimidin-7-one (1) as an inhibitor of Cdk4 led to the initiation of a program to evaluate related pyrido [2,3-d]pyrimidin-7-ones for inhibition of cyclin-dependent kinases (Cdks). Analysis of m
